BioPharmSignal logoBioPharmSignal

Biotech News

Synlogic and Caldera Therapeutics Announce Merger Agreement and Concurrent Private Placement

Synlogic (SYBX)SynlogicFinancing

Combined company to operate as Caldera Therapeutics, developing CLD-423, a potential first-in-class TL1A x IL-23p19 bispecific antibody for inflammatory bowel disease and other immune-mediated diseases Concurrent upsized $278 million private placement committed by a syndicate of leading healthcare

Related news

MNKDMannKind2026-07-24 10:35 EST

MannKind Announces $50 Million Private Placement

MLYSMineralys Therapeutics2026-06-03 10:05 EST

Mineralys Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock

ALTAltimmune2026-04-23 03:25 EST

Altimmune Announces Pricing of $225 Million Oversubscribed Public Offering of Securities

SENSSenseonics2026-05-01 01:50 EST

Senseonics Announces Pricing of $80 Million Public Offering of Common Stock and Pre-Funded Warrants

SGMTSagimet Biosciences2026-04-27 11:15 EST

Sagimet Biosciences Announces Pricing of $175.0 Million Underwritten Offering of Series A Common Stock

SENSSenseonics2026-05-04 20:01 EST

Senseonics Announces Closing of $92 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

MLYSMineralys Therapeutics2026-06-03 10:00 EST

Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing

ALTAltimmune2026-04-22 20:19 EST

Altimmune Announces Proposed Underwritten Public Offering of Securities

ALGSAligos Therapeutics2026-07-30 12:00 EST

Aligos Therapeutics to Announce 2nd Quarter 2026 Financial Results on August 6, 2026

ALGSAligos Therapeutics2026-04-30 20:05 EST

Aligos Therapeutics to Announce 1st Quarter 2026 Financial Results on May 7, 2026

View all latest news

Synlogic

Synlogic was a synthetic-biology company focused on engineered microbes and metabolic disease before its restructuring and decline. Its platform aimed to use living medicines to address rare disorders.

Recent company news

SYBXSynlogic2026-07-29 11:00 EST

Synlogic and Caldera Therapeutics Announce Merger Agreement and Concurrent Private Placement

SYBXSynlogic2024-11-12 21:35 EST

Synlogic Reports Third Quarter 2024 Financial Results

SYBXSynlogic2024-08-08 11:00 EST

Synlogic Reports Second Quarter 2024 Financial Results

SYBXSynlogic2024-05-14 11:00 EST

Synlogic Reports First Quarter 2024 Financial Results

SYBXSynlogic2024-03-19 11:00 EST

Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results

Stock data

Close
1.20 USD
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States